WAVEMAN · COMPANY

BJDX · Bluejay Diagnostics, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

BJDX

Name: Bluejay Diagnostics, Inc. (BJDX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Bluejay Diagnostics, Inc.

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001704287

CLUSTER · 6 INSIDERSACTIVIST 13DC-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$172.8K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$172.8K over 180 days

+$47.8K over 90 days · +$47.8K of it by a 10%+ holder

more than 83% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

6 funds added or opened last quarter

below 94% of Medical Devices

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

$942.3K repurchased, FY to 2026-06-30

below 88% of Medical Devices

SHORT

0.4% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 81% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

6 insiders independently bought a net $172.8K while the stock fell 55% over six months — no planned sales are queued against it.

Northstrive Fund II LP disclosed a 5%+ stake (1.13%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -84.8%

-84.8%12M

INSIDER BUYINSIDER SELL13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

6 insiders reported buying shares.

The record shows a net $172.8K bought by insiders over 180 days, 6 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Bluejay Diagnostics, Inc. insiders bought a net $172.8K of stock across 21 Form 4 purchases and sales, with 6 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

HRT FINANCIAL LP

—

SELL

2026-07-10

34,938.0

$48.9K

HRT FINANCIAL LP

—

BUY

2026-07-09

64,047.0

$96.7K

Wurth Douglas Clark

Director

BUY

2026-03-14

12,500.0

$25.0K

Dey Indranil

President and CEO

BUY

2026-03-14

12,500.0

$25.0K

CHASE DONALD R

Director

BUY

2026-03-14

12,500.0

$25.0K

21 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 16 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

ARMISTICE CAPITAL, LLC

131,000.0 sh

$157.2K

HEIGHTS CAPITAL MANAGEMENT, INC

35,400.0 sh

$42.5K

BOOTHBAY FUND MANAGEMENT, LLC

27,130.0 sh

$32.6K

BANK OF AMERICA CORP /DE/

10,337.0 sh

$12.4K

VANGUARD FIDUCIARY TRUST CO

10,225.0 sh

$12.3K

5%+ owners

13D = intent to influence · 13G = passive

Northstrive Fund II LP

ACTIVIST 13D · 2026-03-11

1.13%

Braeden Lichti

ACTIVIST 13D · 2026-03-11

3.65%

Braeden Lichti

ACTIVIST 13D · 2026-03-11

3.65%

Northstrive Fund II LP

ACTIVIST 13D · 2026-03-11

1.13%

Braeden Lichti

ACTIVIST 13D · 2026-03-11

3.65%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Fidelity Extended Market Index Fund

$18.2K POSITION · AS OF 2026-02-28

0.0%

Fidelity Series Total Market Index Fund

$375 POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 7 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	—	—	—	$249.0K
GROSS PROFIT	—	—	—	$48.9K
OPERATING INCOME	$-7.0M	$-7.2M	$-10.3M	$-9.3M
NET INCOME	$-6.8M	$-7.7M	$-10.0M	$-9.3M
EPS (DILUTED)	-15.25	-456.75	-3,631.48	-9.22
OPERATING CASH FLOW	$-6.1M	$-7.8M	$-8.3M	$-7.7M
CASH	$5.2M	$4.3M	$2.2M	$10.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE